Abstract
The correlates of protective immunity in HIV-1 infection include the endogenous production of compounds with anti-HIV-1 activity. These compounds can be produced independently of specific humoral or cellular immune responses. A model of compartmental inhibition of HIV-1 infection is the placenta, an organ that prevents transmission of HIV-1 to the fetus in the majority of HIV-1 pregnancies. Studies of this organ elucidated new compounds and mechanisms for prevention and treatment of HIV including the potent inhibitor of HIV-1, leukemia inhibitory factor (LIF). Besides coordinating the humoral and cellular immune responses, cytokines such as IFN-? exhibit intrinsic antiviral activity that represents the first line of defense against pathogens prior to the development of a specific immune response. The study of antiviral factors is particularly important in HIV / AIDS because of the direct destruction of the immune system by HIV-1. In this report, we focus on the identification and mechanism of endogenously produced anti-HIV factors and the overall function of these factors in the prevention and treatment of HIV / AIDS.
Keywords: hiv, lif, cytokines, jak, stat, reverse transcription, transcription, placenta
Current Molecular Medicine
Title: Endogenous Inhibitors of HIV: Potent Anti-HIV Activity of Leukemia Inhibitory Factor
Volume: 2 Issue: 8
Author(s): B. K. Patterson, A. Tjernlund and J. Andersson
Affiliation:
Keywords: hiv, lif, cytokines, jak, stat, reverse transcription, transcription, placenta
Abstract: The correlates of protective immunity in HIV-1 infection include the endogenous production of compounds with anti-HIV-1 activity. These compounds can be produced independently of specific humoral or cellular immune responses. A model of compartmental inhibition of HIV-1 infection is the placenta, an organ that prevents transmission of HIV-1 to the fetus in the majority of HIV-1 pregnancies. Studies of this organ elucidated new compounds and mechanisms for prevention and treatment of HIV including the potent inhibitor of HIV-1, leukemia inhibitory factor (LIF). Besides coordinating the humoral and cellular immune responses, cytokines such as IFN-? exhibit intrinsic antiviral activity that represents the first line of defense against pathogens prior to the development of a specific immune response. The study of antiviral factors is particularly important in HIV / AIDS because of the direct destruction of the immune system by HIV-1. In this report, we focus on the identification and mechanism of endogenously produced anti-HIV factors and the overall function of these factors in the prevention and treatment of HIV / AIDS.
Export Options
About this article
Cite this article as:
Patterson K. B., Tjernlund A. and Andersson J., Endogenous Inhibitors of HIV: Potent Anti-HIV Activity of Leukemia Inhibitory Factor, Current Molecular Medicine 2002; 2 (8) . https://dx.doi.org/10.2174/1566524023361817
DOI https://dx.doi.org/10.2174/1566524023361817 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
New Insights into the Surgical Management of Tetralogy of Fallot: Physiological Fundamentals and Clinical Relevance
Current Pediatric Reviews Clinical Pharmacology of Systemic Analgesics in Neonates
Current Drug Therapy Ginkgo biloba as an Alternative Medicine in the Treatment of Anxiety in Dementia and other Psychiatric Disorders
Current Drug Metabolism Current Immune Therapies of Autoimmune Disease of the Nervous System with Special Emphasis to Multiple Sclerosis
Current Pharmaceutical Design Peroxisome Proliferator-Activated Receptor γ Agonists as Insulin Sensitizers: From the Discovery to Recent Progress
Current Topics in Medicinal Chemistry Gene Therapy to Improve High-Density Lipoprotein Metabolism and Function
Current Pharmaceutical Design HLA-DR: Molecular Insights and Vaccine Design
Current Pharmaceutical Design Small Molecule and Biologic Modulators of the Immune Response to Hepatitis C Virus
Mini-Reviews in Medicinal Chemistry Targeting Fibrosis in Systemic Sclerosis
Endocrine, Metabolic & Immune Disorders - Drug Targets Sofosbuvir: Really Meets the Unmet Needs for Hepatitis C Treatment?
Infectious Disorders - Drug Targets Rift Valley Fever Virus
Current Molecular Medicine Vascular Endothelial Growth Factor as an Anti-Angiogenic Target for Cancer Therapy
Current Drug Targets Inflammatory Response and Endothelial Dysfunction Following Cardiopulmonary Bypass: Pathophysiology and Pharmacological Targets
Recent Patents on Inflammation & Allergy Drug Discovery Traversing the Skin Barrier with Nano-emulsions
Current Drug Delivery Comparative Anatomy, Physiology and In Vitro Models of the Blood-Brain and Blood-Retina Barrier
Current Medicinal Chemistry - Central Nervous System Agents Editorial: (Thematic Issue Cancer Immunotherapy: Does an Increasing Arsenal of Tools Point to More Fruitful Avenues for Research?)
Anti-Cancer Agents in Medicinal Chemistry Subthreshold Diode Micropulse Laser Photocoagulation (SDM) as Invisible Retinal Phototherapy for Diabetic Macular Edema: A Review
Current Diabetes Reviews Graphical Abstracts
Letters in Drug Design & Discovery Study of Monocytes/Macrophages Stimuli as the Targets of Treating Inflammatory Bone Diseases
Current Drug Targets Protectors of the Mitochondrial Permeability Transition Pore Activated by Iron and Doxorubicin
Current Cancer Drug Targets